Vienna has a booming life sciences sector that has quickly grown during the last decade. Listed below are 15 biotech corporations within the metropolis you must find out about.
Vienna may not be the primary place that springs to thoughts when pondering of biotech facilities of excellence. However Austria has given its larger neighbors a run for his or her cash in recent times. Since 2010, the variety of biotechs within the nation has greater than doubled. There at the moment are over 150 biotech corporations using over 2,000 folks in Austria, at the least half of that are present in or close to Vienna.
This robust biotech and pharma base in Vienna, which generates billions of euros in income every year, is mirrored by an equally robust historical past of educational science and analysis. The town has 5 universities, two universities of utilized sciences, and eleven analysis institutes.
The biotech sector in Vienna has a powerful concentrate on well being purposes, notably vaccines, diagnostics, and therapeutics for infectious illnesses. This allowed a number of corporations to quickly begin Covid-19 packages after the pandemic began. Vienna additionally has a variety of corporations engaged on diagnostics and biomarkers, most cancers therapeutics, and the cross-section between biotech, IT, and, medtech.
Lots of the metropolis’s youthful biotechs have been established on the Vienna Biocenter, a cluster of life science analysis institutes and firms that homes 38 biotech startups. Following session with native specialists, we put collectively an inventory of essentially the most exceptional biotech corporations to know in Vienna, in no specific order.
Valneva was created when the Austrian biotech Intercell merged with the French biotech Vivalis. Now headquartered in France, the corporate retains a powerful presence in Vienna, in addition to workplaces within the UK, Canada, Sweden, and the US. Valneva is a giant Vienna biotech success story, with a market cap of €1.2B on the Euronext Paris inventory change, and can quickly be launching a Nasdaq IPO.
Valneva has a concentrate on infectious illnesses, specializing in prophylactic vaccines. The corporate has two vaccines already in the marketplace, in opposition to Japanese encephalitis and cholera. It additionally has Zika, Lyme illness, Clostridium difficile, and chikungunya vaccines present process completely different phases of scientific testing. As well as, the corporate is creating an inactivated Covid-19 vaccine, which is at present present process part III testing.
Hookipa Pharma is creating immunotherapies for treating infectious illnesses and most cancers. The therapies use arenaviruses to generate an immune response in opposition to the specified goal.
In November 2020, a part II trial confirmed that the corporate’s lead vaccine candidate is ready to forestall infections and issues in sufferers receiving organ transplants from donors contaminated with cytomegalovirus. The corporate has additionally begun a part I/II trial with an arenavirus-based remedy for cancers brought on by the human papillomavirus.
Hookipa is listed on the Nasdaq inventory change with a market cap of €431M and collaborates with Gilead Sciences to develop practical cures for hepatitis B and HIV.
Initially, Apeiron targeted on creating a drug for acute respiratory misery syndrome. After licensing its drug candidate to GSK, the corporate broadened its pipeline to immuno-oncology. The corporate obtained EU advertising and marketing authorization for its antibody drug Qarziba (dinutuximab beta) in 2017 for the remedy of pediatric neuroblastoma, which is licensed to EUSA Pharma. Apeiron has partnered with huge gamers reminiscent of Evotec, Sanofi, and GSK.
Final 12 months, Apeiron raised €17.5M to fund the event of a Covid-19 remedy primarily based on its early work to deal with sufferers with extreme signs that have acute respiratory misery syndrome. The antibody remedy has lately reported constructive ends in a part IIa trial. The corporate can be creating an autologous mobile remedy to deal with stable tumors as its lead oncology candidate.
Phagomed develops remedies for bacterial infections primarily based on viruses referred to as phages, which selectively infect micro organism. The corporate’s lead drug candidate is an antibacterial chemical referred to as a lysin, extracted from phages, that targets Gardnerella micro organism, identified for inflicting vaginosis. Antibiotics typically don’t work in opposition to bacterial vaginosis and new remedies are desperately wanted. This remedy continues to be on the preclinical part, and the corporate has two different lysins in improvement for undisclosed indications.
Phagomed can be creating a line of phages to focus on joint infections from Staphylococcus aureus, which regularly happen after joint alternative. The primary affected person was efficiently handled utilizing these phages on the finish of March. The corporate has up to now raised greater than €6.5M in non-public investments and public grants.
F2G is an organization with workplaces in Vienna and Manchester that develops novel medication to deal with life-threatening fungal infections. Antifungals are arduous to develop and new options are urgently wanted to fulfill the rising problem of antifungal resistance.
The corporate has produced a brand new class of antifungals referred to as orotomides. Its lead candidate drug, olorofim, is being examined in two part IIb trials in sufferers with fungal infections that don’t have any various remedy choices. The drug targets an enzyme referred to as dihydroorotate dehydrogenase, which is important for the fungi to have the ability to replicate their DNA.
F2G stays a non-public firm and has raised greater than €175M to this point, together with a €50M spherical in August 2020 to fund the late-stage improvement of olorofim.
Haplogen was based as a spin-out of CeMM, the Analysis Heart for Molecular Medication of the Austrian Academy of Sciences, and is positioned on the Vienna BioCenter. The corporate develops antiviral therapies utilizing a genomics platform to establish promising drug candidates. Its most superior candidates are antivirals concentrating on the rhinovirus, which is the principle reason for the frequent chilly in addition to exacerbations of respiratory illness and bronchial asthma.
In 2014, the corporate’s genomics platform was spun out as Haplogen Genomics and in 2015 it was acquired by the Horizon Discovery Group. Haplogen has been companions with the German biotech large Evotec since 2012 and with the large pharma Bayer since 2018.
Ribbon Biolabs is without doubt one of the few non-pharmaceutical biotechs in Vienna. The corporate focuses on making artificial DNA to be used in genetic engineering and genome constructing. Ribbon Biolabs is creating a expertise that writes genetic code utilizing DNA-synthesizing enzymes, which might make the method quicker than chemical synthesis, a way that’s been largely unchanged because the Nineteen Eighties.
The corporate raised over €1.5M in 2018 to fund the event of its expertise, and is at present within the technique of elevating a brand new spherical of funding. Some companions are already utilizing Ribbon’s expertise, however the brand new funding will permit the corporate to increase each technically and commercially.
Austrianni, primarily based on the Vienna Biocenter, is creating antibody therapeutics and antibiotics to stop and deal with tuberculosis. The corporate has a giant library of small drug candidates to attract from, in addition to entry to the antibody discovery platform developed by the US-based firm Trianni, based by Austrianni CSO and Chairman Matthias Wabl.
Austrianni began out with €3M in funding and has since fashioned partnerships with different corporations, reminiscent of Evotec.
Origimm has a concentrate on stopping and treating microbiome-related illnesses, notably dermatological situations regarding the pores and skin microbiome. The corporate’s screening expertise permits it to seek out antigens that confer safety in opposition to damaging micro organism.
Origimm’s lead remedy candidate targets Propionibacterium acnes, the pathogenic micro organism that trigger pimples and implant-associated infections. Its purpose is to each restrict the expansion of P. acnes and to stop the scarring and pores and skin harm brought on by the micro organism. If confirmed efficient, the remedy ought to act each as a prophylaxis and remedy.
Primarily based on the Vienna Biocenter, a:head bio is rising human mind organoids that can be utilized to check remedies for neuropsychiatric problems. The organoids are designed to hold out high-throughput screening of medication concentrating on the central nervous system. From a therapeutic perspective, the corporate’s essential focus is on Dravet syndrome, a uncommon however extreme genetic type of epilepsy.
The corporate attracted greater than €4M non-public and public seed funding in 2019. In February this 12 months, a:head closed one other undisclosed “7-digit” fundraise from European traders.
Allcyte makes use of single-cell picture evaluation to check the efficacy of most cancers drug candidates. The expertise permits the quantification of cell phenotypes individually, which mixed with machine studying and statistics is used to advise clinicians and drug builders on the very best plan of action for his or her sufferers or drug candidates.
The corporate’s drug testing platform has been utilized in a scientific trial of late-stage blood most cancers sufferers to evaluate which medication the sufferers had been almost certainly to reply to. These within the group present process customized drug choice utilizing Allcyte’s platform had been extra possible to reply to remedy and had longer progression-free survival.
In March, Allcyte raised a €5M seed funding spherical following the constructive outcomes from the most cancers trial.
Ares Genetics is a subsidiary of German diagnostics agency Curetis. It was set as much as examine the genetic basis of antibiotic resistance, and to develop new approaches for the speedy analysis of antibiotic resistance in contaminated sufferers, in addition to instruments to speed up antibiotic analysis.
The corporate’s core expertise is a database of genetic antibiotic resistance and susceptibility information, initially developed by Siemens. In 2019, Ares launched an ‘early entry’ program for an antibiotic susceptibility check primarily based on utilizing synthetic intelligence and the corporate’s database to interpret DNA sequencing information. In 2020 the corporate was an early trade responder serving to to trace and management Covid-19.
Proxygen is a younger startup supported by Boehringer Ingelheim, because it received the large pharma’s innovation prize final summer time. This gave the corporate financing for each workplace and laboratory area for a 12 months on the Vienna Biocenter.
The corporate makes a speciality of creating a category of medication they name ‘molecular glue degraders.’ These molecules can goal and destroy dangerous proteins beforehand considered undruggable by reprogramming the cell’s pure protein recycling equipment.
Boehringer Ingelheim and Proxygen introduced in December 2020 that they’ve agreed to collaborate to establish molecular glue degraders which are capable of goal varied varieties of most cancers.
Nabriva Therapeutics has a concentrate on creating new antibiotics, with an FDA and EMA-approved antibiotic in the marketplace, referred to as Xenleta (lefamulin), for the remedy of community-acquired bacterial pneumonia.
Nabriva is at present trialing lefamulin as a remedy for different indications, together with acute bacterial pores and skin and pores and skin construction infections, sexually transmitted infections, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections.
In 2015, Nabriva was the primary Austrian biotech firm to checklist on the Nasdaq inventory change, elevating €82.6M. The corporate now has a market cap of €43.5M and has opened extra workplaces within the US and Eire.
OncoOne is a younger biotech firm specializing in creating most cancers immunotherapies for sufferers with stable tumors that has workplaces within the Austrian city of Klosterneuburg and the Vienna Biocenter. The corporate is researching medication to focus on the oxidized type of a protein referred to as MIF that performs an essential position within the immune system and a possible anti-cancer goal, notably in stable tumors. OncoOne raised a Collection A spherical in March 2020 of €13M with funding from Austrian traders.